WEBULL
WebtradeDownload

What Erasca (ERAS)'s Cancer Drug Trial Start Means For Shareholders

Simply Wall St · 1d ago
  • Erasca and Tango Therapeutics recently started a Phase 1/2 trial testing oral PRMT5 inhibitor vopimetostat with pan RAS molecular glue ERAS-0015 in MTAP-deleted pancreatic cancer and MTAP-deleted or RAS mutant non small cell lung cancer, targeting dose, safety and early antitumor activity.
  • The study highlights how Erasca is trying to expand the practical reach of ERAS-0015 into genetically defined, hard to treat solid tumors, while partnering to share development effort and potentially manage cash use.
  • We will now look at how this new ERAS-0015 combination trial could influence Erasca’s broader investment narrative and risk profile.

Scan how Erasca’s oncology work compares with other high conviction opportunities by reviewing the 19 high quality undiscovered gems that could be flying under most investors’ radar.

Erasca Investment Narrative Recap

Erasca is still an early stage oncology story, so shareholders need to believe that ERAS-0015 and the broader RAS portfolio eventually translate into approved treatments and meaningful commercial use. The near term setup is dominated by clinical execution, safety management and cash discipline, not current revenue, since the company reports US$0 in sales and a loss of US$287.2 million.

The new ERAS-0015 combination trial with Tango fits into that core thesis but, on its own, does not meaningfully change the near term binary risk. The biggest swing factor remains whether planned registration enabling programs and ongoing safety monitoring avoid major setbacks. Legal and intellectual property disputes around ERAS-0015 still sit close to the top of the risk list.

The recently announced Phase 1/2 collaboration with Tango Therapeutics around vopimetostat plus ERAS-0015 looks most relevant for investors tracking Erasca today. It gives the oncology program another shot on goal in MTAP deleted and RAS mutant tumors and adds data flow that could inform how management designs those larger registration enabling studies expected between 2027 and 2028.

Operationally, this study also matters for risk. It is another venue where regulators and clinicians will scrutinize ERAS-0015 safety, which ties directly into concerns after the reported treatment related pneumonitis death and ongoing lawsuits. Positive tolerability and activity from this combination could act as an incremental catalyst, while any serious safety signal would likely amplify the legal and clinical overhang.

Erasca’s current analyst model points to forecast revenue of US$15.4 million and forecast earnings of US$2.7 million by 2029. That profile implies a move from today’s reported earnings loss of US$287.2 million to a positive result, which is an earnings swing of roughly US$289.9 million. Since the company reports no revenue today, the implied top line ramp to US$15.4 million by 2029 functions as the effective revenue growth assumption in the consensus narrative.

Uncover why Erasca's fair value indicates a 62% potential upside to its current price that could narrow quickly.

NasdaqGS:ERAS 1-Year Stock Price Chart
NasdaqGS:ERAS 1-Year Stock Price Chart

Exploring Other Perspectives

Simply Wall St Community members have posted 2 fair value estimates for Erasca, both clustered at US$24.11, so retail sentiment currently points to a single tight anchor. Those views were formed before the Tango trial launch and the November 2026 conference schedule, so fresh data and safety headlines could shift opinions sharply. Readers should expect viewpoints to diverge and should review several alternative takes before forming a stance.

Explore another Erasca fair value estimate, including one that suggests it could be worth just $24.11!

Reach Your Own Conclusion

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

  • A great starting point for your Erasca research is our analysis highlighting 3 important warning signs that could impact your investment decision.
  • See our latest analysis for Erasca. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Erasca's overall financial health at a glance.

Looking For More Ideas Beyond Erasca?

If you want to stress test your thesis on Erasca, it can help to line it up against a few very different setups. The Simply Wall St Screener lets you jump quickly from early stage biotech to more established businesses with very different risk and return profiles.